ATE455791T1 - T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon - Google Patents

T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon

Info

Publication number
ATE455791T1
ATE455791T1 AT06709221T AT06709221T ATE455791T1 AT E455791 T1 ATE455791 T1 AT E455791T1 AT 06709221 T AT06709221 T AT 06709221T AT 06709221 T AT06709221 T AT 06709221T AT E455791 T1 ATE455791 T1 AT E455791T1
Authority
AT
Austria
Prior art keywords
individuals
majority
epstein
epitopes
applications
Prior art date
Application number
AT06709221T
Other languages
German (de)
English (en)
Inventor
Veronique Pancre
Claude Auriault
Stephane Depil
Bernard Maillere
Olivier Morales
Gaetan Munier
Original Assignee
Centre Nat Rech Scient
Commissariat Energie Atomique
Univ Lille Ii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Commissariat Energie Atomique, Univ Lille Ii filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE455791T1 publication Critical patent/ATE455791T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT06709221T 2005-02-07 2006-02-02 T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon ATE455791T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0501198A FR2881746B1 (fr) 2005-02-07 2005-02-07 Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications
PCT/FR2006/000229 WO2006082313A2 (fr) 2005-02-07 2006-02-02 Epitopes t cd4+ des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus db la population caucasienne et leurs applications

Publications (1)

Publication Number Publication Date
ATE455791T1 true ATE455791T1 (de) 2010-02-15

Family

ID=35116028

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06709221T ATE455791T1 (de) 2005-02-07 2006-02-02 T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon

Country Status (8)

Country Link
US (1) US20090130134A1 (enExample)
EP (1) EP1861418B1 (enExample)
JP (1) JP4972562B2 (enExample)
AT (1) ATE455791T1 (enExample)
CA (1) CA2596929C (enExample)
DE (1) DE602006011859D1 (enExample)
FR (1) FR2881746B1 (enExample)
WO (1) WO2006082313A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2174737C (en) * 1993-10-29 2008-04-22 Douglas V. Faller Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents
CA2324426A1 (en) * 1998-02-11 1999-08-19 Douglas V. Faller Compositions and methods for the treatment of cystic fibrosis
FR2830940B1 (fr) 2001-10-17 2007-06-15 Commissariat Energie Atomique Procede de selection de ligands d'hla-dp4 et ses applications
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
SI2083856T1 (sl) 2007-08-15 2011-02-28 Circassia Ltd Peptidi za desenzibilizacijo proti alergijam
WO2010105112A1 (en) * 2009-03-11 2010-09-16 Hemaquest Pharmaceuticals, Inc. Detection of short-chain fatty acids in biological samples
WO2011038224A1 (en) 2009-09-24 2011-03-31 Trustees Of Boston University Methods for treating viral disorders
MA33899B1 (fr) 2009-12-08 2013-01-02 Hemaquest Pharmaceuticals Inc Procedes et regimes a faible dose pour des troubles des globules rouges
US20110245154A1 (en) 2010-03-11 2011-10-06 Hemaquest Pharmaceuticals, Inc. Methods and Compositions for Treating Viral or Virally-Induced Conditions
US9931359B2 (en) 2012-05-08 2018-04-03 The Johns Hopkins University Methods and compositions for infusion of transiently engrafting, selected populations of allogeneic lymphocytes to treat cancer
CN105555756B (zh) 2013-06-28 2018-12-07 奥克兰联合服务有限公司 氨基酸缀合物和肽缀合物及缀合方法
KR20170094449A (ko) 2014-12-23 2017-08-17 마가렛 앤 브림블 아미노산 및 펩타이드 접합체 및 이들의 용도
CN108884020A (zh) 2016-02-26 2018-11-23 奥克兰联合服务有限公司 氨基酸及肽共轭物以及共轭过程
GB2567362B (en) 2016-07-15 2022-04-20 Nantkwest Inc HDAC inhibitors for use with NK cell based therapies
EP3580561B1 (en) 2017-02-12 2023-11-01 BioNTech US Inc. Hla-based methods and compositions and uses thereof
AU2018392884B2 (en) * 2017-12-20 2021-11-11 Glaxosmithkline Biologicals Sa Epstein-Barr Virus antigen constructs
MX2021007556A (es) * 2018-12-21 2021-09-10 Biontech Us Inc Método y sistemas de predicción de epítopos específicos de hla de clase ii y caracterización de células t cd4+.
BR112021024073A2 (pt) 2019-05-31 2022-04-26 Viracta Subsidiary Inc Métodos de tratamento de cânceres associados a um vírus com inibidores de histona desacetilase
US20230100653A1 (en) * 2020-02-10 2023-03-30 The Johns Hopkins University Cancer immunotherapy using transfusions of allogeneic, tumor-specific cd4+ t cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040157780A1 (en) * 1993-11-29 2004-08-12 Epimmune Inc. CTL inducing peptides from c-erb2 (HER-2/neu)
EP0770090A1 (en) * 1994-07-13 1997-05-02 Cornell Research Foundation, Inc. Epstein-barr virus nuclear antigen 1 protein and its expression and recovery
US20020141995A1 (en) * 1997-06-10 2002-10-03 Irvin Charles G. Method for treatment of inflammatory disease
AU783502B2 (en) * 1999-11-24 2005-11-03 Oklahoma Medical Research Foundation Assays and therapies for latent viral infection
EP1229043A1 (en) * 2001-01-30 2002-08-07 Cyto-Barr B.V. Peptides derived from Epstein Barr virus (EBV) proteins LMP1, LMP2 and BARF1 antibody reagents reactive therewith
GB0214528D0 (en) * 2002-06-24 2002-08-07 Univ Aberdeen Materials and methods for induction of immune tolerance
WO2004007536A2 (en) * 2002-07-16 2004-01-22 Affinium Pharmaceuticals, Inc. Interactions of the epstein-barr virus protein ebna1, and uses thereof
WO2004041849A1 (en) * 2002-11-07 2004-05-21 The Council Of The Queensland Institute Of Medical Research Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor
US20040141995A1 (en) * 2002-12-10 2004-07-22 Rongfu Wang MHC class I-restricted and MHC class II-restricted EBNA1 peptides

Also Published As

Publication number Publication date
JP2008529486A (ja) 2008-08-07
CA2596929A1 (fr) 2006-08-10
WO2006082313A2 (fr) 2006-08-10
WO2006082313A3 (fr) 2007-01-11
EP1861418A2 (fr) 2007-12-05
DE602006011859D1 (de) 2010-03-11
US20090130134A1 (en) 2009-05-21
CA2596929C (fr) 2015-12-29
JP4972562B2 (ja) 2012-07-11
FR2881746B1 (fr) 2007-04-13
FR2881746A1 (fr) 2006-08-11
EP1861418B1 (fr) 2010-01-20

Similar Documents

Publication Publication Date Title
ATE455791T1 (de) T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon
EA201070271A1 (ru) Пептиды для получения вакцины
CY1119284T1 (el) ΣΩΜΑΤΙΔΙΑ ΠΑΡΟΜΟΙΑ ΜΕ ΙΟ ΓΛΥΚΟ-ΠΡΩΤΕΪΝΗΣ ΛΥΣΣΑΣ (VLPs)
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
MA30497B1 (fr) Anticorps et immunco-conjugues, et leurs utilisations.
WO2008039267A3 (en) Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
WO2010010467A3 (en) Neutralizing anti-influenza a virus antibodies and uses thereof
CR20130016A (es) ANTICUERPOS PEPTIDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
PH12015501558A1 (en) Human antibodies to respiratory syncytial virus f protein and methods of use thereof
EA201390806A1 (ru) Конструкция пептидного каркаса
EA200801798A1 (ru) Виросомоподобные везикулы, содержащие антигены, производные от gp41
CA2821268C (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
MX341842B (es) Virus de la influenza capaces de infectar canidos y usos de los mismos.
MA44665B1 (fr) Des anti-sirpa anticorps nouvelles et leurs utilisations therapeutiques
MX346475B (es) Peptidos inmunogenicos monomericos y multimericos.
EA201170353A1 (ru) Антитела против гепатита с и их применение
WO2009042895A3 (en) Reagents for inducing an immune response
EA201290792A1 (ru) Пептиды для вакцины против аллергии на березу
WO2008048344A3 (en) Bacillus anthracis antigens, vaccine compositions, and related methods
TW200726479A (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
PT1951300E (pt) Modificação do equilíbrio de th1/th2 em vacinas da influenza fragmentadas com adjuvantes
WO2005023849A3 (en) Antigenic peptides of rabies virus and uses thereof
WO2015086738A3 (en) Hiv vaccine
MX2009003300A (es) Vectores de rhinovirus recombinantes.
BRPI0516576A (pt) vetores quiméricos

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties